Hypothyroidism and Hyperthyroidism

Hypothyroidism and Hyperthyroidism






HYPOTHYROIDISM



Definition and Prevalence


Hypothyroidism results from reduced effects of thyroid hormone on tissues. Hypothyroidism is more common in women, has total prevalence of 1% to 2%,1 and increases with age (~10% adults >65 years). In the U.S. population, prevalence of biochemical hypothyroidism is 4.6%, but clinically evident hypothyroidism is present in 0.3%.2 Congenital hypothyroidism is among the most common congenital diseases, with an incidence of 1/4000 newborns. Higher risk of hypothyroidism is seen in persons with the conditions listed in Box 1.



Hypothyroidism can be congenital or acquired, subclinical or overt, and, according to the site of abnormality, primary (thyroid level) or secondary (pituitary or hypothalamic). The most common causes (Box 2) are Hashimoto’s thyroiditis, postsurgical or postablative hypothyroidism, amiodarone-induced hypothyroidism, and postpartum thyroiditis.







Treatment


Treatment is with thyroid hormone supplementation. Levothyroxine (L-T4) is acceptable therapy for most patients. The starting dose should be 1.6 µg/kg of body weight. In elderly patients and patients with cardiac disease, we recommend starting at a lower dose (25-50 µg/day) and increase by 25 µg/d until the patient is clinically and biochemically euthyroid. The dose should be adjusted about 6 to 8 weeks after treatment is initiated (unless symptoms of overtreatment occur). Once the patient is euthyroid and TSH is stable, an annual follow-up with TSH measurement should suffice. During pregnancy, more-frequent TSH determination are needed because of increasing needs secondary to an increase in binding protein levels. TSH should be checked 2 months after the start or discontinuation of HRT.


The patient should be advised to take the T4 preparation 2 to 4 hours before or after meals or using preparations known to impede T4 absorption: calcium, magnesium, iron, sucralfate, and aluminum hydroxide.


If any signs or symptoms suggest adrenal insufficiency, this should be investigated and, if confirmed, glucocorticoids should be given before starting T4. Failure to do so can precipitate adrenal crisis.


In selected circumstances, T3 may also be used to treat hypothyroidism. Drawbacks to routine use of T3 include short half-life, requiring multiple daily doses, and fluctuating symptoms when doses are missed.


Combination therapy using both T4 and T3 (dessicated thyroid extract, compounded T4-T3 preparation) has been proposed to improve mood and quality of life, but most studies did not show benefit.4 We do not recommend routine use of combination therapy except in cases where fast improvements in clinical condition are required (profound hypothyroidism).


Myxedema coma requires aggressive treatment with intravenous T4 (≤500 µg/day), and some authors recommend addition of T3.5


Consultation with an endocrinologist should be sought in hypothyroid patients who are 18 years old or younger, unresponsive to therapy, or pregnant; who have cardiac disease, goiter, nodule, or other structural abnormality of thyroid gland; or who have another coexisting endocrine disease



HYPERTHYROIDISM



Definition and Prevalence


Thyrotoxicosis is a clinical condition resulting from the action of excess thyroid hormone on tissues. The term hyperthyroidism is usually reserved for thyrotoxicosis caused by excessive production of thyroid hormone (Boxes 3 and 4). Other forms of thyrotoxicosis include thyrotoxicosis factitia and those associated with different forms of thyroiditis. Overt thyrotoxicosis is defined as the syndrome of hyperthyroidism associated with suppressed TSH and elevated serum levels of T4 or T3. Subclinical thyrotoxicosis is devoid of symptoms, but TSH is suppressed although there are normal circulating levels of thyroid hormone.


Jul 18, 2017 | Posted by in GENERAL SURGERY | Comments Off on Hypothyroidism and Hyperthyroidism

Full access? Get Clinical Tree

Get Clinical Tree app for offline access